'Pharma Bro' Martin Shkreli is publicly accusing Capricor Therapeutics (NASDAQ:CAPR) of fraud and alleging legal action will be taken against its CEO and a consultant over patient data.
Shkreli posted on X that "$CAPR is a complete fraud" and later wrote in a separate post that "charges will be brought" on Capricor CEO Linda Marbán and statistics consultant Suzanne Hendrix, claiming they were "playing with patient data." Benzinga has reached out to Capricor Therapeutics for comment and will update this story with any response. the $CAPR is a complete fraud pic.twitter.com/rj9dm1nX3Z— Martin Shkreli (@MartinShkreli) July 27, 2026 charges will be brought on $CAPR CEO @linda_marban & statistics consultant Suzanne Hendrix. having been myself, i am loathe to recommend prison. in this case, i'm making sure you're both going. playing with patient data is a line you cannot cross. in my worst hour i'd never.— Martin Shkreli (@MartinShkreli) July 27, 2026 FDA Documents Raise Concerns Capricor's stock has been under pressure following the release of FDA briefing documents that questioned the effectiveness of its Duchenne cell therapy.
On Monday, shares of Capricor plummeted over 60% after the FDA posted these documents ahead of a July 29 advisory committee meeting.
